TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31479075

Group type: EXPERIMENTAL
Intervention: Therapeutic Couples Intervention (TCI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 150
Study: 30354231

Group type: EXPERIMENTAL
Intervention: Heme arginate 1 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heme arginate 3 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heme arginate infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27419812

Group type: EXPERIMENTAL
Intervention: Oral Pre-Exposure Prophylaxis (PrEP)
Number of subjects: 3226

Group type: EXPERIMENTAL
Intervention: High-risk participants
Number of subjects: 3226
Study: 24606105

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual anti-hyperglycemic therapy
Number of subjects: 12
Study: 22915615

Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor inhibitor
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: ASDAS
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 221
Study: 20552282

Group type: EXPERIMENTAL
Intervention: Automatic advance to the next question with no opportunity to go back (auto/no back)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Automatic advance to the next questions with an opportunity to go back (auto/back)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Next button to go to the next question with no opportunity to go back (next/no back)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Next button to go to the next question with an opportunity to go back (next/back)
Number of subjects: 807

Group type: COMPARATOR
Intervention: Next button (any variant)
Number of subjects: 807
Study: 19126893

Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular release including release of the long head of the biceps tendon
Number of subjects: 88

Group type: COMPARATOR
Intervention: Capsular release alone (Control group)
Number of subjects: 88
Study: 16948965

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical salicylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duct tape
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photodynamic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Er:Yag laser therapies
Number of subjects: 0
Study: 12825127

Group type: EXPERIMENTAL
Intervention: Propagermanium
Number of subjects: 0
Study: 11177200

Group type: EXPERIMENTAL
Intervention: Wholemeal rye bread
Number of subjects: 39

Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 39
Study: 8795326

Group type: EXPERIMENTAL
Intervention: Midazolam (0.04 mg.kg‐1) and Alfentanil (10 micrograms.kg‐1) followed by Propofol (1.25 mg.kg‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alfentanil (10 micrograms.kg‐1) followed by Propofol (1.25 mg.kg‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol only (2.5 mg.kg‐1)
Number of subjects: 90
Study: 1621413

Group type: EXPERIMENTAL
Intervention: Intranasal aerosol administration of quadrivalent inactivated split influenza vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Subcutaneous administration of quadrivalent inactivated split influenza vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline intranasal administration
Number of subjects: 46
Study: 6147641

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 208000

Group type: COMPARATOR
Intervention: High cholesterol control group
Number of subjects: 208000
Study: 31730401

Group type: EXPERIMENTAL
Intervention: TEAMSI-TCM questionnaire
Number of subjects: 38

Group type: COMPARATOR
Intervention: CONTROL questionnaire
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Training in TEAMSI-TCM
Number of subjects: 38

Group type: COMPARATOR
Intervention: Training in CONTROL
Number of subjects: 38
Study: 28001493

Group type: EXPERIMENTAL
Intervention: Video modeling intervention over 6 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 61
Study: 26866433

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg after tracheal intubation and ondansetron 4 mg during skin closure
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dexamethasone and ondansetron
Number of subjects: 117
Study: 24419137

Group type: EXPERIMENTAL
Intervention: MicroRNA signature classifier (MSC)
Number of subjects: 939

Group type: COMPARATOR
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Combination of MSC and LDCT
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: MicroRNA signature classifier (MSC) risk groups
Number of subjects: 939
Study: 22429268

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 5-fluorouracil only (7.5 mg/0.15 mL)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus bevacizumab
Number of subjects: 43

Group type: COMPARATOR
Intervention: 5-fluorouracil only
Number of subjects: 43
Study: 19585925

Group type: EXPERIMENTAL
Intervention: Monitored nutritional regimen (study group)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Conventional prenatal dietary management (control group)
Number of subjects: 257
Study: 17233688

Group type: EXPERIMENTAL
Intervention: Psychiatric intervention (treatment study)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Psychological intervention (prevention study)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Functional tests for mobility and pain measures
Number of subjects: 293
Study: 14649347

Group type: EXPERIMENTAL
Intervention: TIVA with ketamine-midazolam (KM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: halothane-nitrous oxide-oxygen anaesthesia
Number of subjects: 50
Study: 10971683

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (one tablet qds) + amoxicillin (500 mg qds) + metronidazole (400 mg tds)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate (two tablets tds) + amoxicillin (500 mg qds) + metronidazole (400 mg tds)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo bismuth (two tablets tds) + amoxicillin (500 mg qds) + metronidazole (400 mg tds)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bismuth subnitrate (two tablets tds) + placebo antibiotics
Number of subjects: 120
Study: 8967617

Group type: EXPERIMENTAL
Intervention: Pentaglobin therapy (Group 1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No immunoglobulin therapy (Group 2)
Number of subjects: 55
Study: 1474536

Group type: EXPERIMENTAL
Intervention: Nabumetone (1000 mg/day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Indomethacin (75 mg/day)
Number of subjects: 197
Study: 6439566

Group type: EXPERIMENTAL
Intervention: SUL (1 mg/kg i.m.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: SUL + PL (2 ml saline i.v.)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SUL + TRH (200 mcg i.v.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: TRH (200 mcg i.v.)
Number of subjects: 7
Study: 31735388

Group type: EXPERIMENTAL
Intervention: Freestyle bioprosthesis (N = 90)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Homograft (N = 76)
Number of subjects: 166
Study: 28137402

Group type: EXPERIMENTAL
Intervention: Swiss ball exercises with free weights, performed two times per week for 16 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swiss ball exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 26463489

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg qd)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Cefoperazone-sulbactam (3.0 q 8 h)
Number of subjects: 202
Study: 23379974

Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg twice daily for 10 days)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Vancomycin (125 mg 4 times daily for 10 days)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Advancing age (in 10‐year increments)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 999
Study: 21333599

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 134

Group type: COMPARATOR
Intervention: Non-surgical management (Control)
Number of subjects: 134
Study: 19962185

Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvanted vaccine
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1113
Study: 16702779

Group type: EXPERIMENTAL
Intervention: High intensity strength training for 10 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 16825847

Group type: EXPERIMENTAL
Intervention: Music therapy (once a day for 3 days, 30-60 minutes per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no music therapy)
Number of subjects: 40
Study: 10822122

Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 455

Group type: COMPARATOR
Intervention: Nonrandomized patients
Number of subjects: 455
Study: 8675168

Group type: EXPERIMENTAL
Intervention: UDCA (15 mg/kg body weight daily) plus taurine (30 mg/kg body weight daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: UDCA plus placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 1325328

Group type: EXPERIMENTAL
Intervention: High diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Change in dietary intake of 9,11-octadecadienoic acid
Number of subjects: 14
Study: 6152275

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 9
Study: 29903635

Group type: EXPERIMENTAL
Intervention: New technique (NM) - compression with 2 thumbs with closed fists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical technique (MT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New technique (NM)
Number of subjects: 0
Study: 30355117

Group type: EXPERIMENTAL
Intervention: IVT+MT
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: IVT+MT (in patients without anticoagulant medication before stroke onset)
Number of subjects: 381

Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 381
Study: 27716123

Group type: EXPERIMENTAL
Intervention: Bandage contact lens (BCL) application (n=14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No BCL application (control group, n=12)
Number of subjects: 26
Study: 24884885

Group type: EXPERIMENTAL
Intervention: 4 mg of folic acid (FA) daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 0.4 mg of folic acid (FA) daily
Number of subjects: 1000
Study: 23157895

Group type: EXPERIMENTAL
Intervention: Behavioral treatment with naltrexone (22-week comprehensive intervention)
Number of subjects: 40
Study: 20201661

Group type: EXPERIMENTAL
Intervention: Visual laser ablation of urethral strictures (VLASU) with Nd:YAG laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sachse's optical urethrotomy
Number of subjects: 50
Study: 19378423

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (400 mg vitamin C and 180 mg vitamin E d(‐1) and 200 mg BiO‐Quinon Q10 d(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15973918

Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol LCT
Number of subjects: 40
Study: 15339559

Group type: EXPERIMENTAL
Intervention: Jianpi Huoxue Jiedu (JPHXJD) prescription combined with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 10229744

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Trandolapril
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3
Study: 8722437

Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 40000

Group type: COMPARATOR
Intervention: Calcium antagonist (amlodipine)
Number of subjects: 40000

Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitor (lisinopril)
Number of subjects: 40000

Group type: COMPARATOR
Intervention: Alpha-adrenergic blocker (doxazosin)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: HMG CoA reductase inhibitor (pravastatin)
Number of subjects: 40000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40000
Study: 1883797

Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 34
Study: 31421679

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 140
Study: 27955918

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (50 µg) added to lidocaine (9.5 mL) and ropivacaine (10 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (0.5 mL) added to lidocaine (9.5 mL) and ropivacaine (10 mL)
Number of subjects: 60
Study: 25811668

Group type: EXPERIMENTAL
Intervention: Commercial kit with 125I-21OH
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: In-house assay (n=9) using in vitro-translated 35S-21OH or luciferase-labeled 21OH
Number of subjects: 102

Group type: COMPARATOR
Intervention: All laboratories (14 total)
Number of subjects: 102

Group type: COMPARATOR
Intervention: In-house laboratories (n=9)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Commercial kit users (n=5)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Optimized cutoff levels
Number of subjects: 102
Study: 23929441

Group type: EXPERIMENTAL
Intervention: Preventive intervention (social and problem-solving skills training for boys and training for parents on effective child-rearing skills)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 172
Study: 21111770

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (Kavo)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rotary/oscillating instruments
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CeraBur (Komet-Brasseler)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cariex (Kavo)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chemo-mechanical excavation with conventional metal excavators (Carisolv, MediTeam; exp. SFC-V and SFC-VIII, 3M-ESPE)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Plastic excavator with exp. SFC-VIII
Number of subjects: 9
Study: 19158226

Group type: EXPERIMENTAL
Intervention: 20 microg/d cholecalciferol (D3) supplementation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 17453654

Group type: EXPERIMENTAL
Intervention: Protocolized pharmacotherapy with nortriptyline
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Protocolized pharmacotherapy with nortriptyline-plus-lithium
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 15189389

Group type: EXPERIMENTAL
Intervention: Use of IHD guidelines
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aspirin, beta-blockers, and angiotensin converting enzyme inhibitors
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Guideline adherence
Number of subjects: 32
Study: 11699982

Group type: EXPERIMENTAL
Intervention: Antimicrobial agents for caries management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antimicrobial agents
Number of subjects: 0
Study: 9688168

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil capsules containing 1.5 g DHA
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control oil capsules containing 97% soybean oil plus 3% of another fish oil
Number of subjects: 46
Study: 7857355

Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study: 2563388

Group type: EXPERIMENTAL
Intervention: Biotinylated DNA probe
Number of subjects: 63
Study: 805571

Group type: EXPERIMENTAL
Intervention: Radiotherapy (2000 to 2500 rads in two weeks)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 700
Study: 31126004

Group type: EXPERIMENTAL
Intervention: Physical-sport education pilot programme (experimental group, n = 69)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 113
Study: 28992884

Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g/day)
Number of subjects: 86
Study: 26357467

Group type: EXPERIMENTAL
Intervention: LC350189 (10-600 mg single ascending dose)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: LC350189 (100-800 mg multiple ascending dose for 7 days)
Number of subjects: 125

Group type: COMPARATOR
Intervention: LC350189 (200 mg)
Number of subjects: 125
Study: 23851699

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified growing up milk (2.85 μg/100 ml)
Number of subjects: 92
Study: 21516274

Group type: EXPERIMENTAL
Intervention: OFD+β‐TCP
Number of subjects: 12

Group type: COMPARATOR
Intervention: OFD
Number of subjects: 12
Study: 19224790

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) remifentanil (1 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manually controlled continuous infusion (MCI) remifentanil (0.125 microg x kg(‐1) x min(‐1) for 2 min followed by 0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (normal saline either as TCI or manual infusion of equivalent rate)
Number of subjects: 0
Study: 16541851

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus rehabilitation training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rehabilitation training
Number of subjects: 46
Study: 12928909

Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bilateral STN-DBS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (non-operated matched PD patients)
Number of subjects: 16
Study: 11079647

Group type: EXPERIMENTAL
Intervention: Early PCI
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Abciximab with reduced-dose reteplase (5 U double bolus)
Number of subjects: 323

Group type: COMPARATOR
Intervention: No PCI
Number of subjects: 323
Study: 9387746

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (Tapazol and inderal, etc.)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for tonifying Kidney and promoting blood circulation
Number of subjects: 69
Study: 1549034

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3885813

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times daily)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 29127510

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Whole Body Cryotherapy (WBC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 26866405

Group type: EXPERIMENTAL
Intervention: 2-stage injection technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 100
Study: 24827078

Group type: EXPERIMENTAL
Intervention: Bipolar multisite pacing
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unipolar multisite pacing
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atrioventricular single-site pacing
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unipolar pacing
Number of subjects: 17
Study: 21312072

Group type: EXPERIMENTAL
Intervention: Cisplatin plus matrine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (no intraoperative PLC)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Positive PLC patients
Number of subjects: 164
Study: 20383871

Group type: EXPERIMENTAL
Intervention: EPO treatment at a fixed dose of 50 IU/kg per week to increase hemoglobin level to a maximum of 13.7 g/dL for men and 13.4 g/dL for women.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EPO treatment at a fixed dose of 50 IU/kg per week maintaining baseline hemoglobin levels for the first 6 months by phlebotomy.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care without EPO (control group).
Number of subjects: 75
Study: 18609249

Group type: EXPERIMENTAL
Intervention: General practices with older GPs
Number of subjects: 56978

Group type: EXPERIMENTAL
Intervention: General practices in urban locations
Number of subjects: 56978

Group type: EXPERIMENTAL
Intervention: Involvement of practice assistant in diabetes care
Number of subjects: 56978

Group type: EXPERIMENTAL
Intervention: Cooperation with a diabetes nurse
Number of subjects: 56978

Group type: EXPERIMENTAL
Intervention: General practices with younger GPs
Number of subjects: 56978

Group type: EXPERIMENTAL
Intervention: General practices in urban settings
Number of subjects: 56978

Group type: EXPERIMENTAL
Intervention: Appropriate practice organization regarding diabetes care
Number of subjects: 56978

Group type: EXPERIMENTAL
Intervention: Specialty of the GP in diabetes
Number of subjects: 56978
Study: 16293867

Group type: EXPERIMENTAL
Intervention: ICE-V regimen (Ifosfamide, carboplatin, etoposide, and vincristine)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard chemotherapy (cyclophosphamide, doxorubicin, etoposide; cisplatin and etoposide)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: ICE-V regimen
Number of subjects: 402

Group type: COMPARATOR
Intervention: ICE-V regimen and Standard chemotherapy
Number of subjects: 402